;PMID: 1645482
;source_file_897.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..48] = [t:0..48]
;1)sentence:[e:54..202] = [t:54..202]
;2)section:[e:206..241] = [t:206..240]
;3)section:[e:245..304] = [t:245..304]
;4)sentence:[e:308..463] = [t:308..463]
;5)sentence:[e:465..770] = [t:465..770]
;6)sentence:[e:771..965] = [t:771..965]
;7)sentence:[e:966..1132] = [t:966..1132]
;8)sentence:[e:1133..1411] = [t:1133..1411]
;9)sentence:[e:1412..1527] = [t:1412..1527]
;10)sentence:[e:1528..1662] = [t:1528..1662]
;11)sentence:[e:1663..1769] = [t:1663..1769]
;12)sentence:[e:1770..1820] = [t:1770..1820]
;13)sentence:[e:1821..2061] = [t:1821..2061]
;14)sentence:[e:2062..2186] = [t:2062..2186]
;15)sentence:[e:2187..2396] = [t:2187..2396]
;16)sentence:[e:2397..2621] = [t:2397..2621]
;17)section:[e:2625..2669] = [t:2625..2668]
;Sentence Matching Errors
;ERROR_Section end mismatch[e:206..241][t:206..240]
;ERROR_Section end mismatch[e:2625..2669][t:2625..2668]
;Token/POS Errors
;ERROR_Token in entity file but not tree[240..241] .
;ERROR_Token in entity file but not tree[2668..2669] ]

;section 0 Span:0..48
;Toxicol Appl Pharmacol. 1991 Jun 1;109(1):85-97.
(SEC
  (FRAG (NNP:[0..7] Toxicol) (NNP:[8..12] Appl) (NNP:[13..22] Pharmacol)
        (.:[22..23] .) (CD:[24..28] 1991) (NNP:[29..32] Jun) (CD:[33..34] 1)
        (::[34..35] ;) (CD:[35..38] 109) (-LRB-:[38..39] -LRB-) (CD:[39..40] 1)
        (-RRB-:[40..41] -RRB-) (::[41..42] :) (CD:[42..44] 85) (::[44..45] -)
        (CD:[45..47] 97) (.:[47..48] .)))

;sentence 1 Span:54..202
;2,3,7,8-Tetrachlorodibenzo-p-dioxin inhibits steroidogenesis in the rat
;testis  by inhibiting the mobilization of cholesterol to cytochrome P450scc.
;[54..89]:substance:"2,3,7,8-Tetrachlorodibenzo-p-dioxin"
;[168..179]:substance:"cholesterol"
;[183..201]:cyp450:"cytochrome P450scc"
(SENT
  (S-HLN
    (NP-SBJ (NN:[54..89] 2,3,7,8-Tetrachlorodibenzo-p-dioxin))
    (VP (VBZ:[90..98] inhibits)
      (NP (NN:[99..114] steroidogenesis))
      (PP-LOC (IN:[115..117] in)
        (NP (DT:[118..121] the) (NN:[122..125] rat) (NN:[126..132] testis)))
      (PP-MNR (IN:[134..136] by)
        (S-NOM
          (NP-SBJ (-NONE-:[136..136] *))
          (VP (VBG:[137..147] inhibiting)
            (NP
              (NP (DT:[148..151] the) (NN:[152..164] mobilization))
              (PP (IN:[165..167] of)
                (NP (NN:[168..179] cholesterol)))
              (PP (TO:[180..182] to)
                (NP (NN:[183..193] cytochrome) (NN:[194..201] P450scc))))))))
    (.:[201..202] .)))

;section 2 Span:206..240
;Moore RW, Jefcoate CR, Peterson RE
(SEC
  (FRAG (NNP:[206..211] Moore) (NNP:[212..214] RW) (,:[214..215] ,)
        (NNP:[216..224] Jefcoate) (NNP:[225..227] CR) (,:[227..228] ,)
        (NNP:[229..237] Peterson) (NNP:[238..240] RE)))

(ORPH .)

;section 3 Span:245..304
;School of Pharmacy, University of Wisconsin, Madison 53706.
(SEC
  (FRAG (NNP:[245..251] School) (IN:[252..254] of) (NNP:[255..263] Pharmacy)
        (,:[263..264] ,) (NNP:[265..275] University) (IN:[276..278] of)
        (NNP:[279..288] Wisconsin) (,:[288..289] ,) (NNP:[290..297] Madison)
        (CD:[298..303] 53706) (.:[303..304] .)))
;ERROR_Orphan Text from Tree File[240..245] .

;sentence 4 Span:308..463
;Testosterone synthesis in 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-treated 
;rats is decreased because pregnenolone production by the testis is
;inhibited.
;[308..320]:substance:"Testosterone"
;[334..369]:substance:"2,3,7,8-tetrachlorodibenzo-p-dioxin"
;[371..375]:substance:"TCDD"
;[412..424]:substance:"pregnenolone"
(SENT
  (S
    (NP-SBJ-2
      (NP (NN:[308..320] Testosterone) (NN:[321..330] synthesis))
      (PP-LOC (IN:[331..333] in)
        (NP
          (ADJP
            (NML
              (NML (NN:[334..369] 2,3,7,8-tetrachlorodibenzo-p-dioxin))
              (NML (-LRB-:[370..371] -LRB-) (NN:[371..375] TCDD)
                   (-RRB-:[375..376] -RRB-)))
            (HYPH:[376..377] -) (VBN:[377..384] treated))
          (NNS:[386..390] rats))))
    (VP (VBZ:[391..393] is)
      (VP (VBN:[394..403] decreased)
        (NP-2 (-NONE-:[403..403] *))
        (SBAR-PRP (IN:[404..411] because)
          (S
            (NP-SBJ-1
              (NP (NN:[412..424] pregnenolone) (NN:[425..435] production))
              (PP (IN:[436..438] by)
                (NP (DT:[439..442] the) (NN:[443..449] testis))))
            (VP (VBZ:[450..452] is)
              (VP (VBN:[453..462] inhibited)
                (NP-1 (-NONE-:[462..462] *))))))))
    (.:[462..463] .)))

;sentence 5 Span:465..770
;This inhibition can only be caused by a reduction in the activity of the 
;mitochondrial enzyme which converts cholesterol into pregnenolone (cytochrome
; P450scc), and/or by an impairment in the multistep process by which
;luteinizing  hormone (LH) stimulates the mobilization of cholesterol to this
;enzyme.
;[553..559]:substance:"enzyme"
;[575..586]:substance:"cholesterol"
;[592..604]:substance:"pregnenolone"
;[606..625]:cyp450:"cytochrome  P450scc"
;[686..706]:substance:"luteinizing  hormone"
;[708..710]:substance:"LH"
;[743..754]:substance:"cholesterol"
;[763..769]:cyp450:"enzyme"
(SENT
  (S
    (NP-SBJ-3 (DT:[465..469] This) (NN:[470..480] inhibition))
    (VP (MD:[481..484] can)
      (ADVP (RB:[485..489] only))
      (VP (VB:[490..492] be)
        (VP (VBN:[493..499] caused)
          (NP-3 (-NONE-:[499..499] *))
          (PP
            (PP (IN:[500..502] by)
              (NP-LGS
                (NP (DT:[503..504] a) (NN:[505..514] reduction))
                (PP (IN:[515..517] in)
                  (NP
                    (NP (DT:[518..521] the) (NN:[522..530] activity))
                    (PP (IN:[531..533] of)
                      (NP
                        (NP
                          (NP (DT:[534..537] the) (JJ:[539..552] mitochondrial)
                              (NN:[553..559] enzyme))
                          (SBAR
                            (WHNP-2 (WDT:[560..565] which))
                            (S
                              (NP-SBJ-2 (-NONE-:[565..565] *T*))
                              (VP (VBZ:[566..574] converts)
                                (NP (NN:[575..586] cholesterol))
                                (PP (IN:[587..591] into)
                                  (NP (NN:[592..604] pregnenolone)))))))
                        (NP (-LRB-:[605..606] -LRB-)
                           (NN:[606..616] cytochrome) (NN:[618..625] P450scc)
                          (-RRB-:[625..626] -RRB-))))))))
            (,:[626..627] ,) (CC:[628..634] and/or)
            (PP (IN:[635..637] by)
              (NP-LGS
                (NP (DT:[638..640] an) (NN:[641..651] impairment))
                (PP (IN:[652..654] in)
                  (NP
                    (NP (DT:[655..658] the) (JJ:[659..668] multistep)
                        (NN:[669..676] process))
                    (SBAR
                      (WHPP-1 (IN:[677..679] by)
                        (WHNP (WDT:[680..685] which)))
                      (S
                        (NP-SBJ
                          (NP (VBG:[686..697] luteinizing)
                              (NN:[699..706] hormone))
                          (NP (-LRB-:[707..708] -LRB-) (NN:[708..710] LH)
                              (-RRB-:[710..711] -RRB-)))
                        (VP (VBZ:[712..722] stimulates)
                          (NP
                            (NP (DT:[723..726] the) (NN:[727..739] mobilization))
                            (NP (IN:[740..742] of)
                              (NP (NN:[743..754] cholesterol)))
                            (PP (TO:[755..757] to)
                              (NP (DT:[758..762] this) (NN:[763..769] enzyme))))
                          (PP-1 (-NONE-:[769..769] *T*)))))))))))))
    (.:[769..770] .)))

;sentence 6 Span:771..965
;Seven  days after rats were treated with 100 micrograms TCDD/kg, testicular
;cytochrome  P450scc activity (assayed with 20 alpha-hydroxycholesterol as
;substrate) was  decreased to 45% of control.
;[771..776]:quantitative-value:"Seven"
;[778..782]:quantitative-units:"days"
;[812..815]:quantitative-value:"100"
;[816..834]:quantitative-units:"micrograms TCDD/kg"
;[847..866]:cyp450:"cytochrome  P450scc"
;[890..917]:substance:"20 alpha-hydroxycholesterol"
;[921..930]:substance:"substrate"
;[950..953]:quantitative-value:"45%"
(SENT
  (S
    (SBAR-TMP
      (NP-ADV (CD:[771..776] Seven) (NNS:[778..782] days))
      (IN:[783..788] after)
      (S
        (NP-SBJ-2 (NNS:[789..793] rats))
        (VP (VBD:[794..798] were)
          (VP (VBN:[799..806] treated)
            (NP-2 (-NONE-:[806..806] *))
            (PP (IN:[807..811] with)
              (NP
                (NP
                  (NML (CD:[812..815] 100) (NNS:[816..826] micrograms))
                  (NN:[827..831] TCDD))
                (PP (SYM:[831..832] /)
                  (NP (NN:[832..834] kg)))))))))
    (,:[834..835] ,)
    (NP-SBJ-1 (JJ:[836..846] testicular)
      (NML (NN:[847..857] cytochrome) (NN:[859..866] P450scc))
      (NN:[867..875] activity)
      (PRN (-LRB-:[876..877] -LRB-)
        (VP (VBN:[877..884] assayed)
          (NP (-NONE-:[884..884] *))
          (PP (IN:[885..889] with)
            (NP
              (NP (CD:[890..892] 20) (NN:[893..917] alpha-hydroxycholesterol))
              (PP (NN:[918..920] as)
                (NP (NN:[921..930] substrate))))))
        (-RRB-:[930..931] -RRB-)))
    (VP (VBD:[932..935] was)
      (VP (VBN:[937..946] decreased)
        (NP-1 (-NONE-:[946..946] *))
        (PP (TO:[947..949] to)
          (NP
            (NP (CD:[950..952] 45) (NN:[952..953] %))
            (PP (IN:[954..956] of)
              (NP (NN:[957..964] control)))))))
    (.:[964..965] .)))

;sentence 7 Span:966..1132
;If this decrease were responsible for the  inhibition of testicular
;steroidogenesis in vivo, substrate pools for cytochrome  P450scc in the
;testis would be increased.
;[1059..1068]:substance:"substrate"
;[1079..1098]:cyp450:"cytochrome  P450scc"
(SENT
  (S
    (SBAR-ADV (IN:[966..968] If)
      (S
        (NP-SBJ (DT:[969..973] this) (NN:[974..982] decrease))
        (VP (VBD:[983..987] were)
          (ADJP-PRD
            (ADJP (JJ:[988..999] responsible))
            (PP (IN:[1000..1003] for)
              (NP
                (NP (DT:[1004..1007] the) (NN:[1009..1019] inhibition))
                (PP (IN:[1020..1022] of)
                  (NP (JJ:[1023..1033] testicular)
                      (NN:[1034..1049] steroidogenesis)))
                (ADVP (FW:[1050..1052] in) (FW:[1053..1057] vivo))))))))
    (,:[1057..1058] ,)
    (NP-SBJ-1
      (NP (NN:[1059..1068] substrate) (NNS:[1069..1074] pools))
      (PP (IN:[1075..1078] for)
        (NP (NN:[1079..1089] cytochrome) (NN:[1091..1098] P450scc)))
      (PP-LOC (IN:[1099..1101] in)
        (NP (DT:[1102..1105] the) (NN:[1106..1112] testis))))
    (VP (MD:[1113..1118] would)
      (VP (VB:[1119..1121] be)
        (VP (VBN:[1122..1131] increased)
          (NP-1 (-NONE-:[1131..1131] *)))))
    (.:[1131..1132] .)))

;sentence 8 Span:1133..1411
;Yet TCDD decreased the amount of  cholesterol that was readily available to
;cytochrome P450scc in isolated testis  mitochondria (the reactive cholesterol
;pool), even when steroidogenesis was  maximally stimulated in vivo with the
;LH analogue human chorionic gonadotropin  (hCG).
;[1137..1141]:substance:"TCDD"
;[1167..1178]:substance:"cholesterol"
;[1209..1227]:cyp450:"cytochrome P450scc"
;[1275..1286]:substance:"cholesterol"
;[1363..1374]:substance:"LH analogue"
;[1375..1403]:substance:"human chorionic gonadotropin"
;[1406..1409]:substance:"hCG"
(SENT
  (S (CC:[1133..1136] Yet)
    (NP-SBJ (NN:[1137..1141] TCDD))
    (VP (VBD:[1142..1151] decreased)
      (NP
        (NP (DT:[1152..1155] the) (NN:[1156..1162] amount))
        (PP (IN:[1163..1165] of)
          (NP
            (NP (NN:[1167..1178] cholesterol))
            (SBAR
              (WHNP-2 (WDT:[1179..1183] that))
              (S
                (NP-SBJ-2 (-NONE-:[1183..1183] *T*))
                (VP (VBD:[1184..1187] was)
                  (ADJP-PRD (RB:[1188..1195] readily)
                            (JJ:[1196..1205] available)
                    (PP (TO:[1206..1208] to)
                      (NP (NN:[1209..1219] cytochrome) (NN:[1220..1227] P450scc))))
                  (PP-LOC (IN:[1228..1230] in)
                    (NP (JJ:[1231..1239] isolated) (NN:[1240..1246] testis)
                        (NNS:[1248..1260] mitochondria)
                      (PRN (-LRB-:[1261..1262] -LRB-)
                        (NP (DT:[1262..1265] the) (JJ:[1266..1274] reactive)
                            (NN:[1275..1286] cholesterol) (NN:[1287..1291] pool))
                        (-RRB-:[1291..1292] -RRB-))))))))))
      (,:[1292..1293] ,)
      (SBAR-ADV
        (ADVP (RB:[1294..1298] even))
        (WHADVP-1 (WRB:[1299..1303] when))
        (S
          (NP-SBJ-3 (NN:[1304..1319] steroidogenesis))
          (VP (VBD:[1320..1323] was)
            (ADVP (RB:[1325..1334] maximally))
            (VP (VBN:[1335..1345] stimulated)
              (NP-3 (-NONE-:[1345..1345] *))
              (ADVP (FW:[1346..1348] in) (FW:[1349..1353] vivo))
              (PP (IN:[1354..1358] with)
                (NP
                  (NP (DT:[1359..1362] the)
                     (NN:[1363..1365] LH) (NN:[1366..1374] analogue))
                  (NP
                    (NP (JJ:[1375..1380] human) (JJ:[1381..1390] chorionic)
                        (NN:[1391..1403] gonadotropin))
                    (NP (-LRB-:[1405..1406] -LRB-) (NN:[1406..1409] hCG)
                        (-RRB-:[1409..1410] -RRB-)))))
              (ADVP-TMP-1 (-NONE-:[1410..1410] *T*)))))))
    (.:[1410..1411] .)))

;sentence 9 Span:1412..1527
;These decreases in substrate pools were not due to a reduction in 
;mitochondrial capacity for reactive cholesterol.
;[1431..1440]:substance:"substrate"
;[1515..1526]:substance:"cholesterol"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1412..1417] These) (NNS:[1418..1427] decreases))
      (PP (IN:[1428..1430] in)
        (NP (NN:[1431..1440] substrate) (NNS:[1441..1446] pools))))
    (VP (VBD:[1447..1451] were) (RB:[1452..1455] not)
      (PP-PRD (JJ:[1456..1459] due)
        (PP (TO:[1460..1462] to)
          (NP
            (NP (DT:[1463..1464] a) (NN:[1465..1474] reduction))
            (PP (IN:[1475..1477] in)
              (NP
                (NP (JJ:[1479..1492] mitochondrial) (NN:[1493..1501] capacity))
                (PP (IN:[1502..1505] for)
                  (NP (JJ:[1506..1514] reactive) (NN:[1515..1526] cholesterol)))))))))
    (.:[1526..1527] .)))

;sentence 10 Span:1528..1662
;We conclude that the 55%  decrease in cytochrome P450scc activity is not
;severe enough to inhibit  testicular steroidogenesis in vivo.
;[1549..1552]:quantitative-value:"55%"
;[1566..1584]:cyp450:"cytochrome P450scc"
(SENT
  (S
    (NP-SBJ (PRP:[1528..1530] We))
    (VP (VBP:[1531..1539] conclude)
      (SBAR (IN:[1540..1544] that)
        (S
          (NP-SBJ
            (NP (DT:[1545..1548] the)
              (NML (CD:[1549..1551] 55) (NN:[1551..1552] %))
              (NN:[1554..1562] decrease))
            (PP (IN:[1563..1565] in)
              (NP
                (NML (NN:[1566..1576] cytochrome) (NN:[1577..1584] P450scc))
                (NN:[1585..1593] activity))))
          (VP (VBZ:[1594..1596] is) (RB:[1597..1600] not)
            (ADJP-PRD (JJ:[1601..1607] severe) (JJ:[1608..1614] enough)
              (S
                (NP-SBJ (-NONE-:[1614..1614] *))
                (VP (TO:[1615..1617] to)
                  (VP (VB:[1618..1625] inhibit)
                    (NP (JJ:[1627..1637] testicular)
                        (NN:[1638..1653] steroidogenesis))
                    (ADVP (FW:[1654..1656] in) (FW:[1657..1661] vivo))))))))))
    (.:[1661..1662] .)))

;sentence 11 Span:1663..1769
;Instead, TCDD must act by inhibiting the  LH-stimulated mobilization of
;cholesterol to cytochrome P450scc.
;[1672..1676]:substance:"TCDD"
;[1705..1707]:substance:"LH"
;[1735..1746]:substance:"cholesterol"
;[1750..1768]:cyp450:"cytochrome P450scc"
(SENT
  (S
    (ADVP (RB:[1663..1670] Instead))
    (,:[1670..1671] ,)
    (NP-SBJ (NN:[1672..1676] TCDD))
    (VP (MD:[1677..1681] must)
      (VP (VB:[1682..1685] act)
        (PP-MNR (IN:[1686..1688] by)
          (S-NOM
            (NP-SBJ (-NONE-:[1688..1688] *))
            (VP (VBG:[1689..1699] inhibiting)
              (NP
                (NP (DT:[1700..1703] the)
                  (ADJP (NN:[1705..1707] LH) (HYPH:[1707..1708] -)
                        (VBN:[1708..1718] stimulated))
                  (NN:[1719..1731] mobilization))
                (PP (IN:[1732..1734] of)
                  (NP (NN:[1735..1746] cholesterol)))
                (PP (TO:[1747..1749] to)
                  (NP (NN:[1750..1760] cytochrome) (NN:[1761..1768] P450scc)))))))))
    (.:[1768..1769] .)))

;sentence 12 Span:1770..1820
;This conclusion  is supported by two observations.
(SENT
  (S
    (NP-SBJ-1 (DT:[1770..1774] This) (NN:[1775..1785] conclusion))
    (VP (VBZ:[1787..1789] is)
      (VP (VBN:[1790..1799] supported)
        (NP-1 (-NONE-:[1799..1799] *))
        (PP (IN:[1800..1802] by)
          (NP-LGS (CD:[1803..1806] two) (NNS:[1807..1819] observations)))))
    (.:[1819..1820] .)))

;sentence 13 Span:1821..2061
;First, when pregnenolone formation was blocked  by treating rats with the
;cytochrome P450scc inhibitor aminoglutethimide, TCDD  greatly reduced the
;rate at which hCG caused reactive cholesterol to accumulate  in testis
;mitochondria in vivo.
;[1833..1845]:substance:"pregnenolone"
;[1895..1913]:cyp450:"cytochrome P450scc"
;[1914..1923]:substance:"inhibitor"
;[1924..1941]:substance:"aminoglutethimide"
;[1943..1947]:substance:"TCDD"
;[1983..1986]:substance:"hCG"
;[2003..2014]:substance:"cholesterol"
(SENT
  (S
    (ADVP (JJ:[1821..1826] First))
    (,:[1826..1827] ,)
    (SBAR-ADV
      (WHADJP-3 (WRB:[1828..1832] when))
      (S
        (NP-SBJ-2 (NN:[1833..1845] pregnenolone) (NN:[1846..1855] formation))
        (VP (VBD:[1856..1859] was)
          (VP (VBN:[1860..1867] blocked)
            (NP-2 (-NONE-:[1867..1867] *))
            (PP (IN:[1869..1871] by)
              (S-NOM
                (NP-SBJ (-NONE-:[1871..1871] *))
                (VP (VBG:[1872..1880] treating)
                  (NP (NNS:[1881..1885] rats))
                  (PP (IN:[1886..1890] with)
                    (NP
                      (NP (DT:[1891..1894] the)
                        (NML (NN:[1895..1905] cytochrome)
                             (NN:[1906..1913] P450scc))
                        (NN:[1914..1923] inhibitor))
                      (NP (NN:[1924..1941] aminoglutethimide)))))))
            (ADJP-TMP-3 (-NONE-:[1941..1941] *T*))))))
    (,:[1941..1942] ,)
    (NP-SBJ (NN:[1943..1947] TCDD))
    (ADVP (RB:[1949..1956] greatly))
    (VP (VBD:[1957..1964] reduced)
      (NP
        (NP (DT:[1965..1968] the) (NN:[1969..1973] rate))
        (SBAR
          (WHPP-1 (IN:[1974..1976] at)
            (WHNP (WDT:[1977..1982] which)))
          (S
            (NP-SBJ (NN:[1983..1986] hCG))
            (VP (VBD:[1987..1993] caused)
              (S
                (NP-SBJ (JJ:[1994..2002] reactive) (NN:[2003..2014] cholesterol))
                (VP (TO:[2015..2017] to)
                  (VP (VB:[2018..2028] accumulate)
                    (PP-LOC (IN:[2030..2032] in)
                      (NP (NN:[2033..2039] testis)
                          (NNS:[2040..2052] mitochondria)))
                    (ADVP (FW:[2053..2055] in) (FW:[2056..2060] vivo))
                    (PP-1 (-NONE-:[2060..2060] *T*))))))))))
    (.:[2060..2061] .)))

;sentence 14 Span:2062..2186
;Second, TCDD inhibited both testosterone  synthesis and the mobilization of
;cholesterol to cytochrome P450scc within 1  day.
;[2070..2074]:substance:"TCDD"
;[2090..2102]:substance:"testosterone"
;[2138..2149]:substance:"cholesterol"
;[2153..2171]:cyp450:"cytochrome P450scc"
;[2179..2180]:quantitative-value:"1"
;[2182..2185]:quantitative-units:"day"
(SENT
  (S
    (ADVP (JJ:[2062..2068] Second))
    (,:[2068..2069] ,)
    (NP-SBJ (NN:[2070..2074] TCDD))
    (VP (VBD:[2075..2084] inhibited)
      (NP (CC:[2085..2089] both)
        (NP (NN:[2090..2102] testosterone) (NN:[2104..2113] synthesis))
        (CC:[2114..2117] and)
        (NP
          (NP (DT:[2118..2121] the) (NN:[2122..2134] mobilization))
          (PP (IN:[2135..2137] of)
            (NP (NN:[2138..2149] cholesterol)))
          (PP (TO:[2150..2152] to)
            (NP (NN:[2153..2163] cytochrome) (NN:[2164..2171] P450scc)))))
      (PP-TMP (IN:[2172..2178] within)
        (NP (CD:[2179..2180] 1) (NN:[2182..2185] day))))
    (.:[2185..2186] .)))

;sentence 15 Span:2187..2396
;The steroidogenic inhibition does not appear to be due to an LH receptor 
;defect, because TCDD inhibited dibutyryl cAMP- and hCG-stimulated steroid 
;secretion by isolated perfused testes to comparable extents.
;[2248..2259]:substance:"LH receptor"
;[2277..2281]:substance:"TCDD"
;[2292..2306]:substance:"dibutyryl cAMP"
;[2312..2315]:substance:"hCG"
;[2327..2334]:substance:"steroid"
(SENT
  (S
    (NP-3 (DT:[2187..2190] The) (JJ:[2191..2204] steroidogenic)
          (NN:[2205..2215] inhibition))
    (VP (VBZ:[2216..2220] does) (RB:[2221..2224] not)
      (VP (VB:[2225..2231] appear)
        (S
          (NP-SBJ-3 (-NONE-:[2231..2231] *))
          (VP (TO:[2232..2234] to)
            (VP (VB:[2235..2237] be)
              (PP-PRD (JJ:[2238..2241] due)
                (PP (TO:[2242..2244] to)
                  (NP (DT:[2245..2247] an)
                    (NML (NN:[2248..2250] LH) (NN:[2251..2259] receptor))
                    (NN:[2261..2267] defect)))))))
        (,:[2267..2268] ,)
        (SBAR-PRP (IN:[2269..2276] because)
          (S
            (NP-SBJ (NN:[2277..2281] TCDD))
            (VP (VBD:[2282..2291] inhibited)
              (NP
                (NP
                  (ADJP
                    (NML (NN:[2292..2301] dibutyryl) (NN:[2302..2306] cAMP))
                    (HYPH:[2306..2307] -)
                    (ADJP-1 (-NONE-:[2307..2307] *P*)))
                  (NML-2 (-NONE-:[2307..2307] *P*)))
                (CC:[2308..2311] and)
                (NP
                  (ADJP (NN:[2312..2315] hCG) (HYPH:[2315..2316] -)
                    (ADJP-1 (VBN:[2316..2326] stimulated)))
                  (NML-2 (JJ:[2327..2334] steroid) (NN:[2336..2345] secretion))))
              (PP (IN:[2346..2348] by)
                (NP (JJ:[2349..2357] isolated) (JJ:[2358..2366] perfused)
                    (NNS:[2367..2373] testes)))
              (PP (TO:[2374..2376] to)
                (NP (JJ:[2377..2387] comparable) (NNS:[2388..2395] extents))))))))
    (.:[2395..2396] .)))

;sentence 16 Span:2397..2621
;We conclude that  TCDD inhibits testicular steroidogenesis predominantly if
;not exclusively by  inhibiting the mobilization of cholesterol to cytochrome
;P450scc, and that this  inhibition occurs subsequent to cAMP formation.
;[2415..2419]:substance:"TCDD"
;[2524..2535]:substance:"cholesterol"
;[2539..2557]:cyp450:"cytochrome P450scc"
;[2606..2610]:substance:"cAMP"
(SENT
  (S
    (NP-SBJ (PRP:[2397..2399] We))
    (VP (VBP:[2400..2408] conclude)
      (SBAR
        (SBAR (IN:[2409..2413] that)
          (S
            (NP-SBJ (NN:[2415..2419] TCDD))
            (VP (VBZ:[2420..2428] inhibits)
              (NP (JJ:[2429..2439] testicular) (NN:[2440..2455] steroidogenesis))
              (PP
                (ADVP
                  (ADVP (RB:[2456..2469] predominantly))
                  (CONJP (IN:[2470..2472] if) (RB:[2473..2476] not))
                  (ADVP (RB:[2477..2488] exclusively)))
                (IN:[2489..2491] by)
                (S-NOM
                  (NP-SBJ (-NONE-:[2491..2491] *))
                  (VP (VBG:[2493..2503] inhibiting)
                    (NP
                      (NP (DT:[2504..2507] the) (NN:[2508..2520] mobilization))
                      (PP (IN:[2521..2523] of)
                        (NP (NN:[2524..2535] cholesterol)))
                      (PP (TO:[2536..2538] to)
                        (NP (NN:[2539..2549] cytochrome)
                            (NN:[2550..2557] P450scc))))))))))
        (,:[2557..2558] ,) (CC:[2559..2562] and)
        (SBAR (IN:[2563..2567] that)
          (S
            (NP-SBJ (DT:[2568..2572] this) (NN:[2574..2584] inhibition))
            (VP (VBZ:[2585..2591] occurs)
              (S-ADV
                (NP-SBJ (-NONE-:[2591..2591] *))
                (ADJP-PRD (JJ:[2592..2602] subsequent)
                  (PP (TO:[2603..2605] to)
                    (NP (NN:[2606..2610] cAMP) (NN:[2611..2620] formation))))))))))
    (.:[2620..2621] .)))

;section 17 Span:2625..2668
;PMID: 1645482 [PubMed - indexed for MEDLINE
(SEC
  (FRAG (NNP:[2625..2629] PMID) (::[2629..2630] :) (CD:[2631..2638] 1645482)
        (-LRB-:[2639..2640] -LSB-) (NNP:[2640..2646] PubMed) (::[2647..2648] -)
        (VBN:[2649..2656] indexed) (IN:[2657..2660] for)
        (NNP:[2661..2668] MEDLINE)))
;ERROR_Orphan Text from EOF Tree File[2668..EOF] ]

(ORPH -RSB-)
